Long-acting β

Joseph Jude, Nikhil Karmacharya, Rinzhin T Sherpa, Thomas G O'Riordan, Cynthia J Koziol-White, Reynold A Jr Panettieri

Abstract read

In one paragraph

Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joseph Jude *Rutgers Institute for Translational Medicine and Science (RITMS), Rutgers, The State University of New Jersey, 89 French Street, Room 4212, New Brunswick, NJ, 08901, USA. joseph.antonyjude@rutgers.edu.

Nikhil Karmacharya *Rutgers Institute for Translational Medicine and Science (RITMS), Rutgers, The State University of New Jersey, 89 French Street, Room 4212, New Brunswick, NJ, 08901, USA.

Rinzhin T SherpaRutgers Institute for Translational Medicine and Science (RITMS), Rutgers, The State University of New Jersey, 89 French Street, Room 4212, New Brunswick, NJ, 08901, USA.

Thomas G O'RiordanAerogen Pharma Corporation, 1660 S. Amphlett Blvd, Suite 360, San Mateo, CA, 94402, USA.

Cynthia J Koziol-WhiteRutgers Institute for Translational Medicine and Science (RITMS), Rutgers, The State University of New Jersey, 89 French Street, Room 4212, New Brunswick, NJ, 08901, USA.

Reynold A Jr PanettieriRutgers Institute for Translational Medicine and Science (RITMS), Rutgers, The State University of New Jersey, 89 French Street, Room 4212, New Brunswick, NJ, 08901, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To fill the gap in the knowledge between clinical studies and pre-clinical mechanistic studies using combined LABA/LAMA therapy, we hypothesized that the combination is more effective in attenuating excitation-contraction (E-C) coupling compared to either LAMA or LABA alone in human airway smooth muscle (HASM) cells. In primary HASM and human precision-cut lung slices (hPCLS) obtained from non-diseased donors, we show that the combination of umeclidinium (LAMA) and vilanterol (LABA) robustly attenuated carbachol-induced E-C coupling markers, compared to that induced by either compound individually. The effective concentrations of umeclidinium or vilanterol that attenuated E-C coupling signaling events were significantly decreased when the agents were combined as compared to dosing of either alone. In HASM cells treated overnight with albuterol to induce β

Indexed as

Adrenergic beta-2 Receptor AgonistsBenzyl AlcoholsChlorobenzenesMuscarinic AntagonistsMuscle RelaxationMuscle, SmoothQuinuclidinesReceptors, Adrenergic, beta-2TachyphylaxisCells, CulturedDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedMyocytes, Smooth MuscleAdrenergic beta-2 Receptor AgonistsBenzyl AlcoholsChlorobenzenesGSK573719Muscarinic AntagonistsQuinuclidinesReceptors, Adrenergic, beta-2vilanterolAsthmaBronchoconstrictionBronchodilationChronic obstructive lung diseasePersistent airflow obstructionβ2 agonist tolerance

Identifiers

PMID41340126

DOI10.1186/s12931-025-03427-y

PMCPMC12781414

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.